Technology | October 07, 2008

Philips Highlights SPECT/CT, PET/CT

The Philips BrightView XCT integrates Philips BrightView SPECT in a co-planar design with advanced flat-detector X-ray CT technology to acquire low-dose, high-resolution CT images and to improve registration confidence. The system represents the first time a flat panel X-ray detector will be used for CT imaging in nuclear medicine.

The BrightView XCT features technological advances that can enable low patient dose levels, high-resolution localization and high-quality attenuation correction with the potential for fewer artifacts and shorter exam times. This offers clinical advantages particularly in cardiology studies, the top procedure in nuclear medicine. In addition, the co-planar SPECT and CT capabilities limit, and in some cases eliminate, the need to move the table between scans. Reduced movement can help improve patient comfort and allow for more confidence in image registration, the process of comparing, matching and superimposing the SPECT and CT images on one another for analysis. The BrightView XCT is also the only scalable SPECT and SPECT/CT system that fits into a 12-inch by 15.5-inch room and does not require special certification for nuclear medicine technicians.

Additionally, Philips will showcase the new GEMINI TF PET/CT and GEMINI TF PET/CT Big Bore, which features 4D time-of-flight technology, a toolkit to better manage respiratory motion by offering comprehensive tools for combined CT, PET and PET/CT correlated imaging.

The new Philips GEMINI TF Big Bore is the first commercial Big Bore PET/CT, with a full 85 cm bore diameter for both PET and CT scans. The system combines Philips time-of-flight PET imaging technologies with its Brilliance CT Big Bore simulation to optimize oncology workflow, accuracy and patient experience. The GEMINI TF PET/CT Big Bore system is designed to meet the requirements of radiation oncology applications, providing improved planning in cases that call for patients to be in extended positions, such as with treatments of breast and colorectal cancers. The system allows patients to be positioned for simulation in the same manner as they would to receive therapy.

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init